Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech IncfiledCriticalGenentech Inc
Publication of AR104791A1publicationCriticalpatent/AR104791A1/en
Métodos y composiciones terapéuticas y diagnósticos para el cáncer, por ejemplo, cáncer de vejiga. Métodos de tratamiento de cáncer de vejiga, métodos de determinación de si un paciente que está padeciendo cáncer de vejiga probablemente responda al tratamiento que comprende un antagonista de unión al eje de PD-L1, métodos de predicción de la capacidad de respuesta de un paciente que está padeciendo de cáncer de vejiga al tratamiento que comprende un antagonista de unión al eje de PD-L1 y métodos para seleccionar una terapia para un paciente que está padeciendo de cáncer de vejiga, en base a niveles de expresión de un biomarcador de la presente (por ejemplo, niveles de expresión de PD-L1 en células inmunes infiltrantes de tumores en una muestra de tumor obtenida del paciente) y/o sobre la base de la determinación de un Subtipo de muestra de tumor.Therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. Bladder cancer treatment methods, methods of determining whether a patient who is suffering from bladder cancer is likely to respond to treatment that comprises a PD-L1 axis binding antagonist, methods of predicting the responsiveness of a patient who is suffering from bladder cancer treatment that comprises a PD-L1 axis binding antagonist and methods to select a therapy for a patient who is suffering from bladder cancer, based on expression levels of a biomarker present ( for example, expression levels of PD-L1 in tumor infiltrating immune cells in a tumor sample obtained from the patient) and / or based on the determination of a tumor sample subtype.
ARP160101536A2015-05-292016-05-27
THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
AR104791A1
(en)
methods for treatment, for determining compounds to be used, for patient selection, for monitoring therapeutic efficacy, for optimizing therapeutic efficacy, for identifying a biomarker, article of manufacture, use of gdc-0941 , gdc-0941 and an endocrine therapy agent and compound for use